Our new assays have arrived

Using the HTRF^® technology:

2 assays to monitor e-NOS which controls blood vessel dilation, blood pressure, and numerous other anti-atherosclerotic and vasoprotective effects

eNOS Total

Phospho-eNOS (Ser1177)

2 assays to detect total and phosphorylated PLCG1, a cytoplasmic tyrosine kinase that plays a crucial role in signal transduction

PLCg1 Total

Phospho-PLCg1 (Y783)

2 kits to detect the expression of Cereblon, an E3 ubiquitin ligase. Cereblon is a direct target of the immunomodulatory drugs (IMiDs) Thalidomide, Pomalidomide, and Lenalidomide, that are all FDA approved drugs for the treatment of multiple myeloma. IMiDs have recently been derived into PROTAC molecules in order to direct degradation of undesired proteins by the UPS.

Cereblon binding assay (biochemical)

Cereblon Total

Using the AlphaLISA^® SureFire^® Ultra™ technology

p-FGF Receptor 2 (Tyr653/654)

p-FGF Receptor 3 (Tyr724)

FGF Receptor 1 Total

FGF Receptor 2 Total

FGF Receptor 3 Total

FGF Receptor 4 Total

STING Total

p-Rb (Ser780)

p-KAP1 (Ser824)

KAP1 Total

4E-BP1 Total

Using the AlphaLISA^® SureFire^® Ultra™ Multiplex technology:

ERK1/2 p-(Thr202/Tyr204) + ERK Total (New formulation)

Using the Alpha SureFire^® CETSA^® technology:

CDK2

CDK4